IPP Bureau

Bayer Q1 2024 net income drops 8.2% to € 2 billion
Bayer Q1 2024 net income drops 8.2% to € 2 billion

By IPP Bureau - May 14, 2024

EBITDA before special items falls 1.3 percent to € 4.41 billion

Coveris invests over €8 million in production capacity
Coveris invests over €8 million in production capacity

By IPP Bureau - May 14, 2024

Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany

Sanofi India posts Q1 CY24 PAT at Rs. 136.6 Cr
Sanofi India posts Q1 CY24 PAT at Rs. 136.6 Cr

By IPP Bureau - May 14, 2024

Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024

Zydus receives final approval from USFDA for Dexamethasone Tablets
Zydus receives final approval from USFDA for Dexamethasone Tablets

By IPP Bureau - May 13, 2024

Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)

Briefs: Lupin and Aurobindo Pharma
Briefs: Lupin and Aurobindo Pharma

By IPP Bureau - May 13, 2024

Lupin updates on shipment of Mirabegron ER Tablets

Novartis India posts Q4 FY24 net profit lower at Rs. 14.68 Cr
Novartis India posts Q4 FY24 net profit lower at Rs. 14.68 Cr

By IPP Bureau - May 12, 2024

Novartis India has reported total income of Rs. 91.59 crores during the period ended March 31, 2024

Cipla posts Q4 FY24 consolidated PAT at Rs. 939.04 Cr
Cipla posts Q4 FY24 consolidated PAT at Rs. 939.04 Cr

By IPP Bureau - May 11, 2024

The company has posted net profit of Rs. 4,121.55 crores for the Financial Year ended March 31, 2024

Dr. Lal PathLabs posts Q4 FY24 consolidated PAT at Rs. 84.5 Cr
Dr. Lal PathLabs posts Q4 FY24 consolidated PAT at Rs. 84.5 Cr

By IPP Bureau - May 11, 2024

The company has posted net profit of Rs.357.7 crores for the Financial Year ended March 31, 2024

Hester Biosciences posts Q4 FY24 consolidated profit increases to Rs. 4.95 Cr
Hester Biosciences posts Q4 FY24 consolidated profit increases to Rs. 4.95 Cr

By IPP Bureau - May 11, 2024

The company has posted net profit) of Rs.18.88 crores for the Financial Year ended March 31, 2024

OMRON Healthcare India and AliveCor partner to improve heart healthcare in India
OMRON Healthcare India and AliveCor partner to improve heart healthcare in India

By IPP Bureau - May 11, 2024

These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more

Strides receives USFDA approval for Sevelamer Carbonate Tablets
Strides receives USFDA approval for Sevelamer Carbonate Tablets

By IPP Bureau - May 11, 2024

Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment

Ami Organics posts Q4 FY24 consolidated profit at Rs. 25.14 Cr
Ami Organics posts Q4 FY24 consolidated profit at Rs. 25.14 Cr

By IPP Bureau - May 11, 2024

Ami Organics has reported total income of Rs. 226.30 crores during the period ended March 31, 2024

Piramal Pharma posts Q1 FY24 consolidated PAT at Rs. 101.27 Cr
Piramal Pharma posts Q1 FY24 consolidated PAT at Rs. 101.27 Cr

By IPP Bureau - May 11, 2024

Piramal Pharma has reported total income of Rs. 2,578.74 crores during the period ended March 31, 2024

Neuland Laboratories posts Q4 FY24 consolidated PAT at Rs. 67.56 Cr
Neuland Laboratories posts Q4 FY24 consolidated PAT at Rs. 67.56 Cr

By IPP Bureau - May 11, 2024

Neuland Laboratories has reported total income of Rs. 390.36 crores during the period ended March 31, 2024

Alembic Pharmaceuticals receives 5 USFDA product approvals in Q1 FY25
Alembic Pharmaceuticals receives 5 USFDA product approvals in Q1 FY25

By IPP Bureau - May 10, 2024

Receives 3 final and 2 tentative product approvals thus far in Q1FY25

Latest Stories

Interviews

Packaging